4t1乳腺癌細(xì)胞

細(xì)胞名稱：4t1乳腺癌細(xì)胞  小鼠乳腺癌細(xì)胞  

細(xì)胞簡稱：4T1

產(chǎn)品貨號(hào)：TCM-C705

種屬來源：小鼠

組織來源：乳腺

特征：乳腺癌

細(xì)胞形態(tài)：上皮細(xì)胞樣

生長特性：貼壁生長

培養(yǎng)體系：RPMI-1640+10%FBS+1%P/S

4t1乳腺癌細(xì)胞培養(yǎng)基貨號(hào)：TCM-G705

傳代比例：1:3-1:6，每2-3天換液一次

傳代周期：48-72 h

培養(yǎng)條件：氣相：95%空氣+5%CO2，溫度：37℃

凍存條件：60%基礎(chǔ)培養(yǎng)基+30%FBS+10%DMSO，液氮儲(chǔ)存

質(zhì)量檢測(cè)：細(xì)菌、真菌、支原體檢測(cè)均為陰性

    4T1是從410.4瘤株中未經(jīng)誘變篩得的6-硫鳥嘌噙抗性細(xì)胞株。當(dāng)注射到BALB/c小鼠中時(shí)，4T1自發(fā)產(chǎn)生高轉(zhuǎn)移腫瘤，可轉(zhuǎn)移到肺，肝，淋巴結(jié)和大腦，同時(shí)在注射部位形成始發(fā)灶。誘導(dǎo)轉(zhuǎn)移時(shí)不需要摘除始發(fā)灶。4T1細(xì)胞在BALB/c小鼠中的生長與轉(zhuǎn)移特性與人體中的乳腺癌十分相近。這種腫瘤是人VI期乳腺癌的動(dòng)物模型。4T1-誘導(dǎo)的腫瘤在手術(shù)后及未手術(shù)情況下轉(zhuǎn)移的動(dòng)力學(xué)相近，可以用作手術(shù)后及未手術(shù)模型。跟其他腫瘤模型相比，由于4T1的抗6-硫鳥嘌噙特性，微小的轉(zhuǎn)移細(xì)胞團(tuán)(少到僅僅1個(gè))也可以在許多遠(yuǎn)端器官中檢測(cè)到。

參考文獻(xiàn)：

Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed:

Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252

Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed:

Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948